Overview

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion

Status:
Completed
Trial end date:
2017-12-23
Target enrollment:
Participant gender:
Summary
The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.
Details
Lead Sponsor:
Bayer
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept